Lyell Immunopharma (NASDAQ:LYEL) Trading 5.8% Higher

Lyell Immunopharma, Inc. (NASDAQ:LYEL) rose 5.8% during mid-day trading on Monday . The stock traded as high as $2.36 and last traded at $2.36. Approximately 234,559 shares were traded during trading, a decline of 77% from the average daily volume of 1,004,176 shares. The stock had previously closed at $2.23.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their target price on Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th.

Lyell Immunopharma Trading Up 1.2 %

The stock’s 50-day moving average is $2.31 and its 200-day moving average is $2.03.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.01. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $4.96 million. Analysts expect that Lyell Immunopharma, Inc. will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its position in Lyell Immunopharma by 352.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company’s stock valued at $57,000 after acquiring an additional 22,701 shares in the last quarter. Public Employees Retirement System of Ohio increased its stake in Lyell Immunopharma by 109.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock worth $40,000 after buying an additional 14,229 shares during the period. SG Americas Securities LLC increased its position in shares of Lyell Immunopharma by 81.9% during the fourth quarter. SG Americas Securities LLC now owns 99,221 shares of the company’s stock worth $192,000 after acquiring an additional 44,686 shares during the last quarter. Profund Advisors LLC lifted its stake in shares of Lyell Immunopharma by 20.0% in the third quarter. Profund Advisors LLC now owns 73,442 shares of the company’s stock worth $108,000 after acquiring an additional 12,225 shares in the last quarter. Finally, Citigroup Inc. grew its stake in Lyell Immunopharma by 20.0% during the 3rd quarter. Citigroup Inc. now owns 193,739 shares of the company’s stock valued at $285,000 after purchasing an additional 32,225 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.